At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 45 enrolled
Drug / intervention
Ensifentrine Dose 1 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-center, Pilot, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ensifentrine in the Recovery of Hospitalized Patients With COVID-19
In Brief
A Phase 2 clinical trial evaluating Ensifentrine Dose 1 and Placebo pMDI for Coronavirus Infection and 2 related conditions. Completed, enrolled 45 participants across 1 site.
Detailed Summary
This pilot study is being performed to assess the efficacy and safety of inhaled ensifentrine delivered via pMDI compared with a matching placebo in conjunction with standard of care treatments on recovery in patients hospitalized due to COVID-19 infection.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronavirus Infection, Covid-19, SARS-CoV-2
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedAug 2020
Enrollment StartSep 2020
Primary CompletionFeb 2021
Study CompletionMay 2021
TodayJul 2026
First PostedAug 26, 2020
Enrollment StartSep 4, 2020
Primary CompletionFeb 15, 2021
Study CompletionMay 1, 2021
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 5.9 years ago
Interventions
Ensifentrine Dose 1drug
Study drug delivered twice daily via pMDI
Placebo pMDIdrug
Placebo delivered twice daily via pMDI